EUVIMEDEUVIMED entdecken
Open Access

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

Jennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G, Wael Garas, Casey Paleos, Ingmar Gorman, Christopher Nicholas, Michael Mithoefer und 26 weitere

Focus · 2023-07 · 21 (3) · 315-328

DOI: 10.1176/appi.focus.23021011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Focus, 2023-07. Verfasst von Jennifer M Mitchell und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California San Francisco, San Francisco, CA, USA. Department of Psychiatry and Behavioral Sciences, University…. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study. MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was -24.4 (s.d. 11.6) in the MDMA group and -13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation. Appeared originally in Nat Med 2021; 27:1025-1033.

Autor:innen und Institutionen

  • Department of Neurology, University of California San Francisco, San Francisco, CA, USA. Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA. Department of Ps…

Förderung

  • NIDA NIH HHS

Zitieren

APA

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., …, & Doblin, R. (2023). MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Focus, 21(3), 315-328. https://doi.org/10.1176/appi.focus.23021011

Vancouver

Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Focus. 2023;21(3):315-328. doi:10.1176/appi.focus.23021011

BibTeX
@article{Mitchell2023,
  author = {Mitchell, Jennifer M and Bogenschutz, Michael and Lilienstein, Alia and Harrison, Charlotte and Kleiman, Sarah and Parker-Guilbert, Kelly and Ot'alora G, Marcela and Garas, Wael and Paleos, Casey and Gorman, Ingmar and Nicholas, Christopher and Mithoefer, Michael and Carlin, Shannon and Poulter, Bruce and Mithoefer, Ann and Quevedo, Sylvestre and Wells, Gregory and Klaire, Sukhpreet S and van der Kolk, Bessel and Tzarfaty, Keren and Amiaz, Revital and Worthy, Ray and Shannon, Scott and Woolley, Joshua D and Marta, Cole and Gelfand, Yevgeniy and Hapke, Emma and Amar, Simon and Wallach, Yair and Brown, Randall and Hamilton, Scott and Wang, Julie B and Coker, Allison and Matthews, Rebecca and de Boer, Alberdina and Yazar-Klosinski, Berra and Emerson, Amy and Doblin, Rick},
  title = {MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study},
  journal = {Focus},
  year = {2023},
  volume = {21},
  number = {3},
  pages = {315--328},
  doi = {10.1176/appi.focus.23021011}
}
Kostenlos starten →